

Chronic Kidney Disease

Lumantia and the PHARMO Institute are partnering to deliver research insights in Chronic Kidney Disease



Clinical Grouping/Subtyping

- Ability to define clinically meaningful subgroups
- Ability to pathologically confirm diagnosis of rare kidney diseases (e.g., immunoglobulin A nephropathy)
- Characterize current treatment standards overall/per subgroup
- Characterize unmet needs in patients with rare kidney diseases
- Pediatric data are available

Disease & Treatment Characterization

- Patient demographics
- Diagnoses and symptoms
- Treatments (e.g., ACE inhibitors, ARBs)
- Co-medication (heart failure, diabetes)
- Comorbidities
- Clinical parameters, e.g.,
 - Blood pressure
 - UACR
 - HbA1c
 - Creatinine
 - eGFR
 - Proteinuria

Outcomes, Burden of Disease, & Healthcare Resource Utilization

- Clinical labs
 - eGFR
 - Proteinuria
- End-stage renal disease
- Treatments and procedures
- Length of hospital & ICU stay
- Rate of hospital events (e.g., renal failure)
- High-cost medicines use
- Specialist visits
- Malignancy, pathology
- Social demographics

What makes us different



High patient counts in CKD

~90,000 CKD patients







- >20,000 Type 2 Diabetes
- >550 IgAN



A unique, longitudinal, and clinically rich dataset

- 2002 onwards (20+ years)
- Ability to follow through multiple healthcare settings
- Data regularly updated and expanded to include new patients and follow-up information

About PHARMO

-  The PHARMO Institute is an **independent, global leader** in drug safety and outcomes research
-  **The Netherlands has an excellent healthcare system** and is a major hub for clinical trials
-  The **PHARMO Data Network** offers **multi-setting, longitudinal, clinically rich data** with exceptional curation and linkages to hospitals and national registers
-  Dutch data is **representative of Western Europe** and can be used in global studies as a **robust proxy** or complement to EU-5
-  As a founding member of SIGMA Consortium, we can access diverse sources of **pan-European real world data (RWD)** on **>100 million patients**
-  Our capabilities and experience enable us to deliver on a **wide range of real world evidence (RWE) use cases**



⇒ Why choose us?

Luminality can be counted on for service and quality. We utilize proven processes supported by technologically advanced resources to produce high-quality services, with guaranteed satisfaction.